Anteris Technologies Ltd (ASX:AVR, OTC:AMEUF) CEO Wayne Paterson tells Proactive that new data from its first-in-human DurAVR™ transcatheter heart valve trial represent the best results to date at the 30-day mark. The structural heart company presented data from its latest patient cohort at the TVT conference in Arizona last week, showcasing its findings at a summit designed to spotlight cutting-edge research and techniques for structural heart interventions.
Anteris Technologies says latest first-in-human DurAVR™ results are next-level
